patent.fyi
Applications  /  US 2026/0356828
United States Patent Application Publication

US 2026/0356828 A1

Published
Nov 12, 2026
Filed
Jan 14, 2026
Earliest date on the face
Jul 17, 2019
Classification
C07D 417/14
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Lipid solubilization of free base

What ifWhat if a tau degrader with a basic amine is formulated as a free base in a self-emulsifying lipid mixture?
Claim language“a pharmaceutically acceptable salt”

The free base dissolves in a mixture of medium-chain triglycerides and a nonionic surfactant. On aqueous dilution, the mixture forms fine droplets that maintain the compound in a dispersed lipid phase.

1.2Amorphous polymer dispersion

What ifWhat if the tau degrader is dispersed in an amorphous polymer matrix?
Claim language“solvate, polymorph”

The degrader and a vinylpyrrolidone–vinyl acetate copolymer are dissolved together and spray-dried to form a molecular dispersion. The polymer restricts molecular mobility in the dry solid and slows precipitation after hydration.

1.2Direct release of active degrader

What ifWhat if a biodegradable depot releases the active tau degrader directly as the matrix hydrates and erodes?
Claim language“prodrug thereof”

Poly(lactide-co-glycolide) microspheres physically encapsulate the active compound. Water enters the particles and hydrolyzes polymer ester bonds, allowing the intact degrader to diffuse through the developing pore network.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Tau depletion for antibody specificity testing

A reagent quality-control assay uses a tau-binding group linked to a cereblon-binding group to deplete tau in cultured human neuronal cells. Matched cultures receive the bifunctional compound or vehicle, and equal amounts of total lysate protein are loaded on an immunoblot. A reference tau antibody verifies depletion, and the test antibody is scored by whether its bands decrease in the depleted lysate.

Component substitution

Tau recruitment through an IAP ligand

A peptidomimetic ligand for the BIR3 domain of cellular inhibitor of apoptosis protein 1 replaces the cereblon- or VHL-binding group. A linker joins the tau-binding group to a solvent-exposed position on the peptidomimetic and leaves its N-terminal amine free for ligase binding. In cells expressing tau and the recruited ligase, the two binding groups bring tau into proximity with the ligase, and immunoblots track tau and ligase abundance separately.

Parameter or scale variation

Linker length series with fixed termini

A matched series connects the same tau-binding group and cereblon-binding group through linkers containing 2, 4, 6, or 8 ethylene glycol repeat units. The attachment positions and terminal amide bonds stay fixed across the series. Cultured neuronal cells receive each compound at 0.03, 0.1, 0.3, 1, and 3 micromolar for 24 hours, and tau abundance is normalized to total lysate protein to compare the concentration responses.

Pulse dosing and tau recovery profiling

A single compound containing a tau-binding group, a linker, and a cereblon-binding group is applied to parallel neuronal cultures for 1, 4, or 24 hours. At the end of each exposure, the cultures receive three rinses with compound-free medium followed by fresh medium. Separate wells are harvested at washout and at 6, 24, and 48 hours afterward to measure tau abundance relative to time-matched vehicle controls.

Combination with existing systems

Tau degradation in perfused neuronal cultures

A two-channel microfluidic culture device houses human brain endothelial cells and human neurons on opposite sides of a porous membrane. The endothelial channel receives a perfusate containing a tau-binding group linked to a cereblon-binding group. Liquid chromatography with mass spectrometry measures compound exposure in the neuronal channel, and a tau immunoassay measures protein abundance in the neuronal lysate.

Automated or data-driven variant

Image-based ranking of tau degraders

A liquid handler dispenses serial dilutions of linked tau and ligase binders into 384-well plates containing cultured neuronal cells. After incubation, an automated microscope images a tau immunostain and a nuclear stain, and image analysis calculates the median tau signal per cell and the cell count per well. Software fits concentration-response curves against vehicle controls and ranks compounds by maximum tau reduction among wells that retain at least 85 percent of the vehicle-control cell count.

Specific version of a part

Cereblon recruitment through an ether linker

A tau-binding benzothiazole derivative connects through a triethylene glycol spacer to a glutarimide-containing cereblon ligand. The two binding groups bring tau and the cereblon-associated ubiquitin ligase into proximity for ubiquitin transfer.

Hydroxyproline based VHL recruitment

An amide-linked alkyl spacer joins a tau-binding heteroaromatic group to a hydroxyproline-derived VHL ligand. The hydroxyproline group anchors the compound at the VHL substrate-binding site while the other end binds tau.

Crystalline hydrochloride salt

Hydrochloric acid protonates a tertiary amine on the tau degrader in an alcohol solution. Addition of an antisolvent precipitates the crystalline ammonium chloride salt.

Phosphate ester prodrug

A phosphate ester masks a solvent-exposed primary alcohol on the active compound and increases aqueous solubility through phosphate ionization. Phosphatases hydrolyze the ester to regenerate the parent alcohol.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0215731 A1
Published
Aug 2, 2018
Filed
Jan 31, 2018
Class
C07D 401/14
Document BUS 2019/0112307 A1
Published
Apr 18, 2019
Filed
Apr 21, 2017
Class
C07D 471/04
Claim 1
Document A
Document B
1.1PTM-L-ULM,
One aspect discloses a bifunctional compound having the chemical structure: CLM-L-PTM, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or prodrug thereof, wherein: the PTM is a small molecule comprising a protein targeting moiety; the L is a bond or a chemical linking moiety covalently coupling the CLM and the PTM; and the CLM is a small molecule cereblon E3 ubiquitin ligase binding moiety that binds or targets an cereblon E3 ubiquitin liga
A · US 2018/0215731 A1 · ¶ 1416
A bifunctional compound of Formula X: wherein: the Targeting Ligand is capable of binding to CDK8; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase.
B · US 2019/0112307 A1 · claim 1
1.2or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or prodrug thereof,
The present application provides bifunctional compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 8 (CDK8).
B · US 2019/0112307 A1 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.
A · US 2018/0215731 A1 · ¶ 4
The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.
A · US 2018/0215731 A1 · ¶ 3
Alternative strategies to inhibit cyclin-dependent kinases, such as CDK8, are needed.
B · US 2019/0112307 A1 · ¶ 7
The present application relates to novel bifunctional compounds, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
B · US 2019/0112307 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0356828 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356828/, SHA-256 5dd53c2b3852c5c11d3aaff44b684f4a200fc4b192a2c2f37b7eae40819a574a
First published
Permanent addresshttps://patent.fyi/US20260356828/
Content fingerprint (SHA-256)5dd53c2b3852c5c11d3aaff44b684f4a200fc4b192a2c2f37b7eae40819a574a
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi